Baxalta company information, Employees & Contact Information

Shire to Acquire Baxalta for $32 Billion CHEManager

Baxalta and Momenta part ways on adalimumab biosimilar Generics and Biosimilars Initiative

Shire buys Baxalta for $32 billion, ending months-long pursuit BioPharma Dive

Baxalta Biologics Facility, Georgia, US Pharmaceutical Technology

Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict Fierce Pharma

Genentech beats back Baxalta patent lawsuit over hemophilia drug Reuters

Shire, Baxalta Complete $32B Merger Genetic Engineering and Biotechnology News

Shire to Buy Baxalta for $32 Billion the-scientist.com

Shire Agrees to Buy Baxalta for $32 Billion The Wall Street Journal

Shire to buy Baxalta for $32B USA Today

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark Fierce Biotech

Shire-Baxalta Merger Will Create a Giant in Drugs for Rare Diseases (Published 2016) The New York Times

Shire Holds Talks With Baxalta That May Lead to Takeover Bloomberg.com

As Baxalta-Shire Merger Grinds to a Close, Baxalta Lays Off 239 in California BioSpace

Analysts skeptical about Shire’s Baxalta ‘growth play’ strategy BioPharma Dive

Pharma mania: Shire offers $30B for Baxalta USA Today

After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen Fierce Biotech

With Baxalta in hand, Shire's not looking to buy. But sell? Maybe Fierce Pharma

Baxalta CEO touts new R&D model with a focus on development BioPharma Dive

FDA approves Baxalta’s longer-lasting hemophilia A drug BioPharma Dive

GCV Powerlist 2016: Geeta Vemuri, Baxalta - Global Corporate Venturing

Baxalta Spins Off from Baxter Genetic Engineering and Biotechnology News

Shire Wins Baxalta With Revised $32 Billion Bid, Adding Cash Bloomberg.com

Merck, Amgen and Baxalta back a $315M biotech fund from venBio Fierce Biotech

Baxalta CEO to leave after all Crain's Chicago Business

Baxter boosts Baxalta share exchange offer MassDevice

Shire pharmaceutical makes $30bn move for Baxalta The Guardian

Shire Said in Advanced Talks to Acquire Drugmaker Baxalta Bloomberg.com

Baxter names biopharma spin-off Baxalta PMLiVE

Baxalta, Shire to Pay $4.8M to Resolve Unpaid Overtime Claims Class Action Lawsuits

Shire’s Offer to Buy Drug Maker Baxalta for $30 Billion Is Rebuffed (Published 2015) The New York Times

T.O.’s Baxalta sold to an Irish firm Camarillo Acorn

Drugmaker Shire to buy Baxalta for $32 billion after 6-month pursuit Reuters

Its official: Baxalta launches The Covington News

Baxter spinoff to employ 800 at Bannockburn HQ Crain's Chicago Business

Baxalta and CTI complete filing for Jakafi rival in US PMLiVE

Baxalta agrees to $32bn Shire takeover PMLiVE

Zell company courts Baxter spinoff for HQ lease Crain's Chicago Business

The commercial real estate media source. NEREJ

Reports: $32bn Shire takeover of Baxalta close to done deal Pharmafile

Shire and Baxalta drugs among CHMP’s latest recommendations PMLiVE

Why has Shire joined the biotech bonanza with Baxalta bid? The Guardian

Baxalta’s Enbrel biosimilar measures up in late-stage study Pharmafile

Shire moves to seal Baxalta deal with improved offer Pharmafile

Shire clinches $32bn takeover of Baxalta The Guardian

With Shire takeover bid looming, Baxalta CEO offers plan for growth The Boston Globe

What Can We Learn From TRC Capital's Mini-Tender Offers? Seeking Alpha

Competition Commission clears Baxter-Baxalta deal The Economic Times

Shire goes public with proposed $30 billion Baxalta tie-up El Economista